RecruitingPhase 1Phase 2NCT06995573

A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease

A Phase 2a, Multi-Center, Randomized, Parallel Group, Double Blind and Placebo-controlled Clinical Trial to Assess Safety and Tolerability as Well as Explorative Efficacy of the Orthosteric Selective Muscarinic M1 Agonist NSC001 in Mild to Moderate Alzheimer's Disease

Sponsor

NSC-Therapeutics

Enrollment

90 participants

Start Date

Aug 25, 2025

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease

Summary

The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.

Eligibility

Min Age: 50 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called NSC001 and Placebo for people with alzheimer disease. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 50 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNSC001

rigid, orthosteric acetylcholine analog, highly specific for M1 muscarinic receptor

OTHERPlacebo

matching placebo to NSC001

Locations(10)

Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft GmbH

Salzburg, State of Salzburg, Austria

University Hospital Graz

Graz, Styria, Austria

Medical University Innsbruck

Innsbruck, Austria

Medical University Vienna

Vienna, Austria

Clinic Altenburger Land GmbH

Altenburg, Germany

Zentrum fuer klinische Forschung Dr. I. Schoell GmbH

Bad Homburg, Germany

University Clinic Köln

Cologne, Germany

Universitaetsmedizin Goettingen

Göttingen, Germany

Dynamikos GmbH Institut fuer Studien zur Psychischen Gesundheit

Mannheim, Germany

SANOS Clinic

Ratingen, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06995573

Related Trials

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787292 locations

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229258 locations